Discontinued — last reported Q2 '22
Repatha (evolocumab) — Total revenues
Products & Services · Total revenuesAmgen Repatha (evolocumab) — Total revenues decreased by 1.2% to $325.00M in Q2 2022 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ3 2020
Last reportedQ2 2022
Rolls up toTotal Revenue
How to read this metric
An increase reflects successful market penetration and sustained therapeutic adoption, whereas a decrease may signal patent cliffs, generic competition, or loss of market share.
Detailed definition
This metric captures the total net revenue attributed to the specific therapeutic product line after all adjustments for...
Peer comparison
Comparable to net product sales reported by peer biotech companies for their key commercialized assets.
Metric ID:
amgn_segment_repatha_evolocumab_total_revenuesHistorical Data
4 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | |
|---|---|---|---|---|
| Value | $286.00M | $272.00M | $329.00M | $325.00M |
| QoQ Change | — | -4.9% | +21.0% | -1.2% |
| YoY Change | — | — | — | +13.6% |
Range$272.00M – $329.00M
Avg YoY Growth+13.6%
Median YoY Growth+13.6%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's repatha (evolocumab) — total revenues?
- Amgen (AMGN) reported repatha (evolocumab) — total revenues of $325.00M in Q2 2022.
- What does repatha (evolocumab) — total revenues mean?
- The total net revenue generated by the specific therapeutic product after all commercial adjustments.